OpenAI acquires Orchestra Bio, plans to bring its technology into Rosalind

OpenAI announced it has acquired Orchestra Bio, a platform that helps biopharma teams coordinate drug development. Madison Mills reports in Axios that OpenAI plans to integrate Orchestra's team and technology into Rosalind, its suite of AI models and tools for life-sciences researchers.

Axios reports that Orchestra's platform lets scientists delegate monitoring studies, tracking drug-development timelines and identifying potential delays to AI agents. On , Orchestra describes agents handling planning, orchestration and analysis while scientists and program leaders retain decisions requiring their expertise. Orchestra says drug development spans discovery, preclinical, manufacturing and clinical work.